AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Tezspire (tezepelumab by Year
Tezspire (tezepelumab — direct product sales) — Worldwide product sales ($M) ($M)
AstraZeneca Tezspire (tezepelumab: $458M in FY2025, up 84.7% from a year earlier.
Where the FY2025 figure comes from
“|| Tezspire | 458 | 85 | 80 | - | - | 40 | n/m | n/m | 297 | 90 | 83 | 121 | 51 | 51”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Tezspire (tezepelumab — direct product sales) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 458 | +84.7% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 248 | +188.4% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 86 | +2,050.0% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 4 | – | Form 6-K FY2022Q4 Earnings Release ↗ |
Breakdown
What makes up tezspire (tezepelumab
- Tezspire (tezepelumab — direct product sales) — Worldwide YoY actual (%)85.0% · FY2025
- Tezspire (tezepelumab — direct product sales) — Worldwide YoY CER (%)80.0% · FY2025
- Tezspire (tezepelumab — direct product sales) — US product sales ($M)0 · FY2025
- Tezspire (tezepelumab — direct product sales) — Emerging Markets product sales ($M)40 · FY2025
- Tezspire (tezepelumab — direct product sales) — Europe product sales ($M)297 · FY2025
- Tezspire (tezepelumab — direct product sales) — Established RoW product sales ($M)121 · FY2025
Cite this data
StockData. (2026). AstraZeneca Tezspire (tezepelumab ($M), annual FY2022–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-tezspire-world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.